BREAKING NEWS

Medicare issued a preliminary decision to cover the Alzheimer's drug Aduhelm only for patients who participate in approved clinical trials.

Tuesday, January 11, 2022 4:36 PM EST

The drug was approved by the Food and Drug Administration in June in a decision criticized by many experts because clinical trials showed it had significant safety risks and unclear benefit to patients.

Whether Medicare ends up covering Aduhelm is considered pivotal to the future of the drug, which is priced at $28,200 a year per patient.

Read the latest